HR+/HER2- Metastatic Breast Cancer

α-Specific PI3K inhibitors are emerging as potential treatment options for HR+/HER2- metastatic breast cancer.⁹

The PI3K pathway is the most frequently mutated signaling pathway across all breast cancer subtypes, and PIK3CA mutations are the most common alterations in the PI3K pathway¹⁰
Patients with HR+/HER2- metastatic breast cancer who have a PIK3CA mutation have a worse prognosis than those without PIK3CA alterations¹⁰